Spherix Incorporated – Product Pipeline Review – H2 2011
Summary
Global Market Direct’s pharmaceuticals report, “Spherix Incorporated - Product Pipeline Review - H2 2011” provides data on the Spherix Incorporated’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Spherix Incorporated’s corporate website, SEC filings, investor presentations and featured press releases, both from Spherix Incorporated and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
Reasons to buy
Summary
Global Market Direct’s pharmaceuticals report, “Spherix Incorporated - Product Pipeline Review - H2 2011” provides data on the Spherix Incorporated’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Spherix Incorporated’s corporate website, SEC filings, investor presentations and featured press releases, both from Spherix Incorporated and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Spherix Incorporated - Brief Spherix Incorporated overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Spherix Incorporated human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Spherix Incorporated with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Spherix Incorporated’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Spherix Incorporated’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Spherix Incorporated in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Spherix Incorporated’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Spherix Incorporated.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Spherix Incorporated and identify potential opportunities in those areas.
Spherix Incorporated Snapshot
Spherix Incorporated Overview
Key Information
Key Facts
Spherix Incorporated – Research and Development Overview
Key Therapeutic Areas
Spherix Incorporated – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Spherix Incorporated – Pipeline Products Glance
Spherix Incorporated – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Spherix Incorporated–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Spherix Incorporated – Drug Profiles
Naturlose
SPX 10624258
SPX 7233801
SPX 8522876
SPX 8818309
SPX 8818440
SPX-106 + D-tagatose
SPX106
Spherix Incorporated – Pipeline Analysis
Spherix Incorporated – Pipeline Products by Therapeutic Class
Spherix Incorporated - Pipeline Products By Target
Spherix Incorporated – Pipeline Products by Route of Administration
Spherix Incorporated – Pipeline Products by Molecule Type
Spherix Incorporated – Recent Pipeline Updates
Spherix Incorporated – Company Statement
Spherix Incorporated – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Apr 30, 2008: Spherix Announces Update On D-Tagatose
Oct 24, 2011: Spherix Announces Results From New Preclinical Studies Showing SPX-106T Produces Significant Reductions In Cholesterol, Fat Deposition And Body Weight
Jun 24, 2009: Spherix Announces Positive Phase 2 Study Results
Jun 23, 2010: Spherix Expands Development Strategy For D-Tagatose
Nov 16, 2009: Spherix Announces Positive Interim Results In Phase 3 Trial Of Novel, Oral Compound For Type 2 Diabetes
Jun 14, 2008: Spherix Expands Phase 3 Naturlose Diabetes Trial Outside Of The US
Jan 12, 2010: Spherix Completes Enrollment Of Naturlose, Phase 3 Clinical Trial Evaluating Naturlose For Type 2 Diabetes
Sep 08, 2011: Spherix's SPX-106T Treatment Yields Significant Reductions In Serum VLDL And LDL Cholesterol In Mice
Oct 07, 2010: Spherix Announces Results From Phase III Study Of D-tagatose In Type 2 Diabetes
Jun 02, 2011: Spherix's SPX-106 Shows Statistically Significant Reductions In Serum Triglycerides In Preclinical Testing
May 01, 2007: Spherix Announces Start Of Phase 3 Clinical Trial
Financial Deals Landscape
Spherix Incorporated, Deals Summary
Spherix Incorporated, Pharmaceuticals & Healthcare, Deal Details
Licensing Agreements
Biospherics Enters Into Licensing Agreement With University Of Kentucky Research Foundation
Spherix Enters Into Licensing Agreement With Albert Einstein College of Medicine
Equity Offering
Spherix Completes Private Placement Of Common Stock For $1.3 Million
Spherix Completes Registered Direct Offering Of Units For $3 Million
Spherix Completes Private Placement Of Series B Convertible Preferred Stock For $5 Million
Spherix Completes Registered Direct Offering Of $6.3 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Spherix Incorporated – Pipeline by Therapy Area and Indication, H2 2011
Spherix Incorporated – Pipeline by Stage of Development, H2 2011
Spherix Incorporated – Monotherapy Products in Pipeline, H2 2011
Spherix Incorporated – Combination Treatment Modalities in Pipeline, H2 2011
Spherix Incorporated – Phase III, H2 2011
Spherix Incorporated - Pipeline By Therapeutic Class, H2 2011
Spherix Incorporated - Pipeline By Target, H2 2011
Spherix Incorporated – Pipeline By Route of Administration, H2 2011
Spherix Incorporated – Pipeline By Molecule Type, H2 2011
Spherix Incorporated – Recent Pipeline Updates, H2 2011
Spherix Incorporated, Subsidiaries
Spherix Incorporated, Deals Summary
Biospherics Enters Into Licensing Agreement With University Of Kentucky Research Foundation
Spherix Enters Into Licensing Agreement With Albert Einstein College of Medicine
Spherix Completes Private Placement Of Common Stock For $1.3 Million
Spherix Completes Registered Direct Offering Of Units For $3 Million
Spherix Completes Private Placement Of Series B Convertible Preferred Stock For $5 Million
Spherix Completes Registered Direct Offering Of $6.3 Million
LIST OF FIGURES
Spherix Incorporated – Pipeline by Therapy Area and Indication, H2 2011
Spherix Incorporated – Pipeline by Stage of Development, H2 2011
Spherix Incorporated – Monotherapy Products in Pipeline, H2 2011
Spherix Incorporated – Combination Treatment Modalities in Pipeline, H2 2011
Spherix Incorporated – Pipeline By Therapeutic Class, H2 2011
Spherix Incorporated - Pipeline By Target, H2 2011
Spherix Incorporated Overview
Key Information
Key Facts
Spherix Incorporated – Research and Development Overview
Key Therapeutic Areas
Spherix Incorporated – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Spherix Incorporated – Pipeline Products Glance
Spherix Incorporated – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Spherix Incorporated–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Spherix Incorporated – Drug Profiles
Naturlose
SPX 10624258
SPX 7233801
SPX 8522876
SPX 8818309
SPX 8818440
SPX-106 + D-tagatose
SPX106
Spherix Incorporated – Pipeline Analysis
Spherix Incorporated – Pipeline Products by Therapeutic Class
Spherix Incorporated - Pipeline Products By Target
Spherix Incorporated – Pipeline Products by Route of Administration
Spherix Incorporated – Pipeline Products by Molecule Type
Spherix Incorporated – Recent Pipeline Updates
Spherix Incorporated – Company Statement
Spherix Incorporated – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Apr 30, 2008: Spherix Announces Update On D-Tagatose
Oct 24, 2011: Spherix Announces Results From New Preclinical Studies Showing SPX-106T Produces Significant Reductions In Cholesterol, Fat Deposition And Body Weight
Jun 24, 2009: Spherix Announces Positive Phase 2 Study Results
Jun 23, 2010: Spherix Expands Development Strategy For D-Tagatose
Nov 16, 2009: Spherix Announces Positive Interim Results In Phase 3 Trial Of Novel, Oral Compound For Type 2 Diabetes
Jun 14, 2008: Spherix Expands Phase 3 Naturlose Diabetes Trial Outside Of The US
Jan 12, 2010: Spherix Completes Enrollment Of Naturlose, Phase 3 Clinical Trial Evaluating Naturlose For Type 2 Diabetes
Sep 08, 2011: Spherix's SPX-106T Treatment Yields Significant Reductions In Serum VLDL And LDL Cholesterol In Mice
Oct 07, 2010: Spherix Announces Results From Phase III Study Of D-tagatose In Type 2 Diabetes
Jun 02, 2011: Spherix's SPX-106 Shows Statistically Significant Reductions In Serum Triglycerides In Preclinical Testing
May 01, 2007: Spherix Announces Start Of Phase 3 Clinical Trial
Financial Deals Landscape
Spherix Incorporated, Deals Summary
Spherix Incorporated, Pharmaceuticals & Healthcare, Deal Details
Licensing Agreements
Biospherics Enters Into Licensing Agreement With University Of Kentucky Research Foundation
Spherix Enters Into Licensing Agreement With Albert Einstein College of Medicine
Equity Offering
Spherix Completes Private Placement Of Common Stock For $1.3 Million
Spherix Completes Registered Direct Offering Of Units For $3 Million
Spherix Completes Private Placement Of Series B Convertible Preferred Stock For $5 Million
Spherix Completes Registered Direct Offering Of $6.3 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Spherix Incorporated – Pipeline by Therapy Area and Indication, H2 2011
Spherix Incorporated – Pipeline by Stage of Development, H2 2011
Spherix Incorporated – Monotherapy Products in Pipeline, H2 2011
Spherix Incorporated – Combination Treatment Modalities in Pipeline, H2 2011
Spherix Incorporated – Phase III, H2 2011
Spherix Incorporated - Pipeline By Therapeutic Class, H2 2011
Spherix Incorporated - Pipeline By Target, H2 2011
Spherix Incorporated – Pipeline By Route of Administration, H2 2011
Spherix Incorporated – Pipeline By Molecule Type, H2 2011
Spherix Incorporated – Recent Pipeline Updates, H2 2011
Spherix Incorporated, Subsidiaries
Spherix Incorporated, Deals Summary
Biospherics Enters Into Licensing Agreement With University Of Kentucky Research Foundation
Spherix Enters Into Licensing Agreement With Albert Einstein College of Medicine
Spherix Completes Private Placement Of Common Stock For $1.3 Million
Spherix Completes Registered Direct Offering Of Units For $3 Million
Spherix Completes Private Placement Of Series B Convertible Preferred Stock For $5 Million
Spherix Completes Registered Direct Offering Of $6.3 Million
LIST OF FIGURES
Spherix Incorporated – Pipeline by Therapy Area and Indication, H2 2011
Spherix Incorporated – Pipeline by Stage of Development, H2 2011
Spherix Incorporated – Monotherapy Products in Pipeline, H2 2011
Spherix Incorporated – Combination Treatment Modalities in Pipeline, H2 2011
Spherix Incorporated – Pipeline By Therapeutic Class, H2 2011
Spherix Incorporated - Pipeline By Target, H2 2011
